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Abstract
Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays an essential role in neuronal development and
plasticity. MicroRNA (miRNAs) are small non-coding RNAs of about 22-nucleotides in length regulating gene expression at
post-transcriptional level. In this study we explore the role of miRNAs as post-transcriptional inhibitors of BDNF and the
effect of 39UTR sequence variations on miRNAs binding capacity. Using an in silico approach we identified a group of
miRNAs putatively regulating BDNF expression and binding to BDNF 39UTR polymorphic sequences. Luciferase assays
demonstrated that these miRNAs (miR-26a1/2 and miR-26b) downregulates BDNF expression and that the presence of the
variant alleles of two single nucleotide polymorphisms (rs11030100 and rs11030099) mapping in BDNF 39UTR specifically
abrogates miRNAs targeting. Furthermore we found a high linkage disequilibrium rate between rs11030100, rs11030099
and the non-synonymous coding variant rs6265 (Val66Met), which modulates BDNF mRNA localization and protein
intracellular trafficking. Such observation led to hypothesize that miR-26s mediated regulation could extend to rs6265
leading to an allelic imbalance with potentially functional effects, such as peptide’s localization and activity-dependent
secretion. Since rs6265 has been previously implicated in various neuropsychiatric disorders, we evaluated the distribution
of rs11030100, rs11030099 and rs6265 both in a control and schizophrenic group, but no significant difference in allele
frequencies emerged. In conclusion, in the present study we identified two novel miRNAs regulating BDNF expression and
the first BDNF 39UTR functional variants altering miRNAs-BDNF binding.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the
neurotrophins family, which consists of small secreted proteins
playing crucial roles in activity-dependent processes, such as
synapses development and plasticity [1]. BDNF promotes
neuronal survival and differentiation of specific populations of
embryonic neurons in peripheral and central nervous system and
shows also in adulthood a crucial regulatory role in key functions,
including neuronal homeostasis and brain plasticity-related
processes such as learning and memory [2–3].
Several DNA variants mapping within the BDNF genomic
region have been associated with a number of human traits, such
as performance on intelligence tests, various cognitive functions,
personality, and memory [4–8]. Notably, there are many
evidences for BDNF contribution to the pathogenesis of several
neuropsychiatric disorders. To date BDNF has been reported to be
associated with schizophrenia [9–12], Parkinson’s disease [13–16],
addictive substance use or dependence [17], Alzheimer’s disease
[18–19], bipolar disorder or depression [20–23] and obsessive-
compulsive disorder [24]. In particular, the common non-
conservative single nucleotide polymorphism (SNP) rs6265
(G.A), resulting in a Valine to Methionine aminoacid change
at codon 66 in the pro-domain of BDNF protein (pro-BDNF), has
been extensively analysed in several neuropsychiatric disorder
through linkage and association studies leading to conflicting
results [25–29]. This functional polymorphism was shown to affect
the ability to perform verbal episodic memory tasks and
hippocampal function [4], to influence BDNF mRNA localization,
putatively impairing dendritic targeting of BDNF transcript [30]
and to alter the intracellular distribution and activity-dependent
secretion of the BDNF protein [31].
MicroRNAs (miRNAs) are small non-coding RNAs of about 22-
nucleotides in length regulating gene expression at post-transcrip-
tional level. Once processed from longer stem-loop-like precursors
they are guided to target mRNA sequences by base-pairing
39UTR, resulting in the cleavage of target mRNAs or repression of
their translation [32]. The seed region is the critical region for
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complementariness and consists of nucleotides 2–8 from the
miRNA 59 [33]. To date, miRNAs have been shown to be
involved in many physiological processes, such as differentiation,
proliferation, apoptosis and morphogenesis [34] and pathological
events, i.e. cardiac hypertrophy [35], muscle dystrophy [36],
hepatitis infection [37], diabetes [38], Parkinson’s disease [39],
haematological malignancies [40] and other types of cancer [41]
and psychiatric and neurodevelopmental disorders [42–44].
Human BDNF expression is controlled by complex mecha-
nisms, indeed its transcription is regulated by multiple promoters
driving the expression of different coding transcripts [45]. It has
been recently observed that genes bearing multiple binding sites
for transcription factors (TF) show higher probabilities to be
targeted by miRNAs and to harbour more miRNA-binding sites
on average [46]. This observation indicates that genes with
higher cis-regulation complexity are more co-coordinately
regulated by TFs at transcriptional level and by miRNAs at
post-transcriptional level [46]. This has been partly demonstrated
by in silico analysis of human BDNF 39UTR sequence using
bioinformatics tools predicting the presence of several putative
miRNA target sites. To date some of these sites have been
experimentally validated (miR-1/206 [47]; miR-30a, miR-30a-5p
and miR-195 [48]; miR-124 and let-7d [49]; miR-15a [50];
miR-210 [51]).
Recent studies on human miRNA target sequences suggested
that the nucleotide variants mapping in these regions could alter
miRNA directed translation silencing likely contributing to
diversity of human phenotypes [52,53]. Such mechanism was
described in two patients affected by Tourette syndrome
harbouring a 39UTR rare sequence variant in the SLITRK1 gene
reinforcing a target site for miR-189 [54]. Since then, several
papers demonstrated the effects of miRNA binding sites variations
in asthma, hypertension and aggressive behaviour [55–57].
In the present work we demonstrated through in silico and
experimental approaches that BDNF expression is regulated by a
group of miRNAs. We also investigated whether common allelic
variants in BDNF sequence may influence miRNA targeting and
thus participate to BDNF expression modulation. We identified
two common polymorphisms (rs11030100 and rs11030099)
mapping to the 39UTR of the longest BDNF mRNA isoform
and demonstrated that they modulate the interaction with two
different miRNAs. Finally, we considered the rs6265 coding SNP,
which was previously associated to various neuropsychiatric
diseases and assessed the haplotype containing this variant and
the two 39 UTR polymorphic sites within a schizophrenic and a
control sample.
Results
Bioinformatics analysis
Bioinformatics approaches have been applied to identify
miRNAs potentially binding to human BDNF 39UTR and to
assess the presence of sequence variations in miRNA binding sites.
From the analysis of PolymiRTS Database [58] three polymorphic
sites were identified (rs11030100 C.A, rs11030099 G.T and
rs7124665 C.A, dbSNP build 130) (Table 1). The first two SNPs
were predicted to affect the same hypothetical seed region of miR-
26a (encoded by two different genomic loci miR-26a1 and miR-
26a2) and miR-26b. The third polymorphism (rs7124665) was
predicted to create a new binding site for miR-374. From the
Predicted Targets component of miRecords miR-26a and -26b are
predicted to target BDNF by at least 3 and 2 different programs
respectively, miR-374 at least by 2 programs (Table 2).
Genotype analysis of BDNF 39UTR polymorphisms
A group of 176 Caucasian control subjects was collected in
order to estimate allelic frequencies at the polymorphic sites.
rs7124665 resulted not to be variable, while rs11030100 and
rs11030099, mapping two nucleotides apart one from the other,
were polymorphic (Table 3). Genotypic distribution was in Hardy-
Weinberg equilibrium for both variants (chi
2=1.99, p=0.16,
df=1). The ancestral allele of both SNPs, was determined by
human versus chimpanzee (Pan troglodytes) genome alignment and it
was always observed in the same haplotype suggesting that the two
variants could have arisen in a single mutational event. MiRNA
binding site sequences containing the two polymorphic sites have
Table 1. SNPs that modify miRNA binding sites according to PolymiRTS Database.
Location SNP ID Ancestral Allele Allele miR ID
(a) Support miRSite
(b) Func Class
2884 rs11030100 C C miR-26a miR-26b 1 ccaagACTTGAAg N
A
2887 rs11030099 G T
G miR-26a miR-26b 1 agACTTGAAggtg N
3383 rs7124665 C C
A miR-374 0 TATTATAtttgta C
PolymiRTS Database uses the criteria of TargetScan for miRNA binding sites prediction.
(a)Support column indicates occurrence of the miRNA site in other vertebrate genomes in addition to the query genome.
(b)Function Class specifies if the derived allele either disrupts a non conserved miRNA site (N) or creates a new miRNA site (C).
doi:10.1371/journal.pone.0028656.t001
Table 2. Analysis output with miRecords, that integrates
predicted miRNA targets produced by 11 miRNA target
prediction programs.
miRNA ID miRanda PITA RNAhybrid
hsa-miR-26a !! !
hsa-miR-26b !!
hsa-miR-374a !!
hsa-miR-374b !
Here are reported programs that predict BDNF 39UTR miRna binding sites for
miRNAs identified with PolymiRTS. Other programs are: DIANA-microT,
MicroInspector, MirTarget2, miTarget, NBmiRTar, PicTar, TargetScan and RNA22.
doi:10.1371/journal.pone.0028656.t002
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high sequence conservation among primate genomes (Fig. 1).
MiR-26a and -26b interact with human BDNF 39UTR
We focused the experiments on miR-26a and -26b since in silico
analysis predicted these miRNAs as targeting BDNF through base
pairing to 39UTR sites that resulted to be polymorphic from
genotype analysis (rs11030100 and rs11030099). In order to
functionally validate the computational data, a dual-luciferase
assay was performed in HeLa cells. The activity of the reporter
plasmid with ancestral alleles at polymorphic sites (pluc-BDNF C-
G) in the presence of each of the two miRNAs was significantly
lower than those of cells transfected with miR-control or
unmodified pRL-TK vector, indicating that BDNF was specifically
down-regulated by miR-26a and miR-26b miRNA mimics (33%
and 43% respectively, Fig. 2).
From these results we could conclude that human BDNF is
targeted by miR-26a and miR-26b which bind to the same seed
sequence.
BDNF allelic variants decrease miR-26s binding ability
Sequence analysis demonstrated that the derivative alleles of
rs11030100 (A) and rs11030099 (T) were contemporaneously
present for both SNPs. Since those variants created two potential
mismatches between BDNF 39UTR seed sequence and miR-26a
and 26b (Fig. 3) we hypothesized that they may impair miR-26s
targeting. To validate this hypothesis, we tested the interaction
between mutant BDNF transcripts and both miR-26a and -26b. In
agreement with our assumption, when the reporter constructs
were cotransfected with either miR-26a or miR-26b, no
modification of the luciferase signal of the pRL-TK vector
carrying the derivative alleles (pluc-BDNF A-T) could be observed
(Fig. 2), as obtained with miR-control or unmodified pRL-TK. We
could conclude that allelic variants at rs11030100 and rs11030099
sites abrogate miR-26s mediated translation suppression.
Genotype analysis of BDNF miR26-a and –b binding site
in a schizophrenic sample
In order to analyze the allelic distribution of the identified
polymorphisms in a psychiatric disease sample, a group of 70
schizophrenic patients was collected and genotyped for the
fragments containing rs11030100, rs11030099 and rs7124665.
As for the control group (see Results section, ‘‘Genotype analysis of
BDNF 39UTR polymorphisms’’ paragraph), the latter SNP resulted
not to be polymorphic, while rs11030100 and rs11030099 were
polymorphic. The ancestral allele of both SNPs was always
observed in the same haplotype combination (see Table 3 for allele
and genotype frequencies) and the genotypic distribution for each
polymorphism was in Hardy-Weinberg equilibrium (chi
2=1.57,
p=0.21, df=1). No significant differences in the allelic distribution
were observed between case and control samples for each SNP.
Genotype analysis of rs6265 coding SNP
rs6265 SNP was genotyped both in case and control subjects.
Met allele frequency (Table 4) was consistent with reported allele
Table 3. Allele and genotype frequencies of BDNF
polymorphisms rs11030100-rs11030099 in control subjects
and schizophrenic patients.
Genotypes Alleles N
BDNF
rs11030100-
rs11030099 C/C-G/G C/A-G/T A/A-T/T C–G A–T
Control
subjects
0.57 0.39 0.04 0.77 0.23 176
Schizophrenic
patients
0.68 0.26 0.06 0.81 0.19 70
doi:10.1371/journal.pone.0028656.t003
Figure 1. Multiple genome alignment of BDNF 39UTR in the region of polymorphic sites rs11030100 and rs11030099 (in bold
letters). Sequence analysis shows that sites are highly conserved among primate genomes.
doi:10.1371/journal.pone.0028656.g001
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genotypic distribution of rs6265 for both groups of cases and
controls were in Hardy-Weinberg equilibrium (chi
2=3.38,
p=0.07, df=1 and chi
2=0.40, p=0.53, df=1 respectively). No
significant differences in the allelic distribution of rs6265 and
rs11030100-rs11030099 in the schizophrenic and control samples
was evidenced.
Pairwise linkage disequilibrium between BDNF
polymorphisms and haplotype association analysis
In order to assess the level of linkage disequilibrium (LD)
between rs6265 and rs11030100 and rs11030099 we studied the
BDNF genomic region. We assessed the haplotype structure for 43
control subjects (/139) and 15 patients (/70) samples who resulted
to be heterozygous for the coding SNP rs6265 and for the 39UTR
SNPs (rs11030100 and rs11030099) through amplification and
cloning of a fragment comprising the polymorphic sites. The
haplotype structure and the LD extent in both samples have been
computationally predicted and experimentally assessed through
double restriction enzyme analysis. A nearly complete LD was
found between the three SNPs in both case and control group.
The extent of LD between the polymorphic sites was determined
by calculating the D9 statistics. LD (D9) calculated and estimated
(in parenthesis) in control subjects and schizophrenic samples was
0.89 (0.91) and 0.89 (1) respectively.
Four haplotypes consisting of alleles for the BDNF SNPs were
observed. The most represented haplotype was ‘‘Val-C-G’’
(respectively rs6265, rs11030100, rs11030099) showing a frequen-
cy of 75% in control and 80% schizophrenic sample. The second
most frequent haplotype was ‘‘Met-A-T’’ which accounted for
19% in control and 15% in schizophrenic subjects. Other
haplotypes were less frequent (Val-A-T 4% in both groups and
Met-C-G 2% and 1%). The comparison of haplotype frequencies
Figure 2. Luciferase assays for validation of miR-26a and -26b binding to BDNF 39UTR. HeLa cells were independently transfected with
control plasmid (pRL-TK) or each of the two reporter plasmid (pluc-BDNF C–G, anc, and pluc-BDNF A–T, der) with either miR-26a or miR-26b. Data are
presented as the normalized activity of different reporter genes. Introduction of exogenous miR-26a and miR-26b represses reporter activity of pluc-
BDNF C–G but has no effect on pluc-BDNF A–T. Data represent the mean of five independent experiments +SD (p,0.05).
doi:10.1371/journal.pone.0028656.g002
Figure 3. Schematic representation of base pairing between
miR-26a sequence and BDNF 39UTR ancestral (C–G) and
derivative (A–T) alleles of rs11030100 and rs11030099 poly-
morphic sites. MiR-26b has the same seed binding sequence.
doi:10.1371/journal.pone.0028656.g003
Table 4. Allele and genotype frequencies of BDNF
polymorphism rs6265 (Val66Met) in control subjects and
schizophrenic patients.
Genotypes Alleles N
BDNF Val66Met
(rs6265) Val/Val Val/Met Met/Met Val Met
Control subjects 0.63 0.34 0.03 0.80 0.20 176
Schizophrenic
patients
0.73 0.21 0.06 0.84 0.16 70
doi:10.1371/journal.pone.0028656.t004
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Discussion
The regulation of mRNA stability and translation through
miRNAs represents a mechanism directing and influencing gene
expression widely described in mammals [34]. DNA sequence
variations at miRNA binding sites could affect the base-pairing
process between a miRNA and its target, hence making the
miRNA-mediated gene repression ineffective and putatively
leading to phenotypic effects [59–60]. Indeed, it has been recently
suggested that such events underlie the onset of cancer [61] and
various other pathological conditions [55–57].
Using different bioinformatic tools we identified a group of
miRNAs, namely miR-26a-1, miR-26a-2, miR-26-b and miR-374,
supposedly regulating BDNF translation by binding to three
annotated polymorphic sites. MiR-26a1, -26a2 and -26b bind to a
BDNF 39UTR sites whose sequence is not conserved among
mammals. This may explain the small number of programs
predicting this putative binding site since many algorithms mainly
depend on conservation over a large range of species, thus target
prediction results biased against newly evolved miRNA target sites.
Interestingly, narrowing the genome comparison analysis only to
higher primates, miR-26s seed binding sequence results to be
highly conserved suggesting that this regulatory circuitry could be
recently acquired in primate evolution.
To date BDNF 39UTR structure has been poorly characterized
and most studies focused on 59UTR and coding sequence [62].
Several studies have focused on rat BDNF gene structure which
can be alternatively polyadenylated directing the synthesis of at
least two transcripts differing in 39UTR size [63–64] and
exhibiting different properties such as the turnover rate at
activated synapses [65]. More recently it has been demonstrated
in a murine model that these two isoforms show a diverse neuronal
localization [66] and that the distinct 39UTRs differentially
regulate BDNF translation in response to neuronal activity changes
[67]. Multiple polyadenylation and highly conserved sequences
have been also reported in human genome [68] leading to the
hypothesis that the same regulatory mechanism may exist in
humans as well. MiR-26s binding site is exclusively present in the
long BDNF mRNA isoform suggesting that miRNAs mediated
regulation could account for the differential properties of BDNF
mRNA isoforms such as stability and localization.
MiR-26a1, -26a2 and -26b belong to a miRNAs family showing
a highly conserved sequence and sharing the same seed sequence.
They are coded by different genome loci which map in the
intragenic regions of paralog genes (CTDSPL, CTDSP2, CTDSP1).
As we demonstrate that miR-26s binding site is polymorphic
(rs11030100 and rs11030099), a regulatory effect could be exerted
by the affinity rank between miRNA and its binding site. In
particular, as the target for both miR-26a and -26b is exclusively
the rs11030100 and rs11030099 ancestral allele only the BDNF
mRNA carrying the ancestral genotype would be regulated by
these miRNAs. Noteworthy, miR-26s are differentially expressed
in tissues and are highly expressed in brain where they play a
crucial role in neural cells specification [69,70]. These observa-
tions taken together with the expression data available in public
databases lead to hypothesize the existence of an overlapping
expression pattern of miR-26s and BDNF in brain so that the
39UTR SNPs abrogating miRNA regulation would hold a
functional role only in those areas expressing the cognate
miRNAs.
We further extended the analysis to rs6265 SNP which maps in
the coding sequence of pro-BDNF and which is the best
characterized BDNF functional variant to date. rs6265 is
associated with modulation of intracellular trafficking and
packaging of pro-BDNF, that acts as a dimer, and consequently
with the secretion of the activity-dependent mature peptide [4,31].
It has been demonstrated that this SNP has an effect also on BDNF
mRNA localization, putatively impairing dendritic targeting of
BDNF transcript [30]. Interestingly, nearly complete LD between
rs6265 and SNPs rs1130100 and rs11030099 was found both in
case and control samples allowing to hypothesize that miR-26s
mediated regulation could extend to rs6265 leading to an allelic
imbalance potentially modulating its functional effect on both
mRNA and protein. In particular, it could be assumed that the
most represented haplotype carrying the ancestral alleles at each
polymorphic site could contribute to regulate the expression of the
more functional Val allele in modulation of intracellular trafficking
leading to proper secretion of the activity-dependent mature
peptide.
The involvement of rs6265 in the susceptibility to various
psychiatric disorders and especially schizophrenia has been
extensively investigated through linkage and association studies
leading to conflicting results [25–29]. Since large allelic frequen-
cies variations of the rs6265 SNP have been reported in population
of different ethnic origins, it has been proposed that a yet
unidentified causal variant could possibly lie within or nearby
BDNF. On the other hand, literature data about miR-26a and
miR-26b pointed out some evidences about the role of these
miRNAs in brain functions, such as stress response [70], and in
schizophrenia susceptibility [71–72]. In particular, the association
between schizophrenia and sequence variants in miRNA genes
was evaluated in a case-control study demonstrating that a
polymorphism mapping to the genomic region adjacent to miR-
26a-1 showed allelic association to schizophrenia [71]. Recently it
has been reported that miR-26b was expressed at lower levels in
the prefrontal cortex of schizophrenia versus comparison subjects
[72]. Therefore, we studied the distribution of rs6269, rs11030100
and rs11030099 in a sample of schizophrenic subjects and
compared the results with the normal control sample. No
significant differences in the allelic and haplotypic distribution
emerged from the comparison of schizophrenic and control
subjects but this result may not be not conclusive because of the
small sample size. It would be crucial to study the involvement of
these variants in psychiatric disorders pathogenesis in large case-
control samples.
Provided that BDNF structure and expression is extremely
complex, as recently stated by several studies, detailed knowledge
of novel regulatory sequences may contribute to understand cell-
specific and activity-dependent regulation of BDNF expression
offering new interesting information that could be related to
physiologic and pathogenetic mechanisms in which BDNF is
involved.
The present study demonstrated that miR-26a and miR-26b
mediate BDNF expression regulation and lead to identity the first
BDNF 39UTR functional variants (rs1130100 and rs11030099)
altering miRNAs-BDNF binding. These polymorphisms have been
evaluated in a haplotypic context showing nearly complete LD
with rs6265 coding SNP.
Materials and Methods
Bioinformatic analysis
Information about BDNF genomic region were obtained from
the genome browser of the University of California, Santa Cruz
(http://genome.ucsc.edu). BDNF gene and mRNA sequences were
from RefSeq (http://www.ncbi.nlm.nih.gov/RefSeq) and Gen-
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miRTS (Polymorphism in miRNA Target Site) database was
interrogated (http://compbio.uthsc.edu/miRSNP) to identify
sequence variations in putative miRNA binding sites. MiRecords
(http://mirecords.biolead.org/) was used to predict binding sites
for miRNAs on BDNF 39UTR. Information about BDNF and
miRNAs expression was obtained from public databases (http://
www.genecards.org, http://biogps.org, http://mirnamap.mbc.
nctu.edu.tw).
Subjects
70 patients with schizophrenia (35 males; mean age 6 SD,
28.4566.32 years) and 176 healthy subjects (45 males; mean age
6 SD, 32.8869.74 years) were recruited for the present study at
Department of Neuroscience, University of Rome Tor Vergata.
All participants were unrelated, white Caucasians from Rome and
surrounding urban areas. Diagnosis of schizophrenia was reached
by consensus between two experienced psychiatrists by using
DSM-IV-TR based Structured Clinical Interview (SCID). Healthy
subjects underwent SCID to exclude any DSM-IV-TR Axis I
disorder. None of the patients and controls had a history of
significant drug or alcohol abuse, head trauma with loss of
consciousness, or significant medical illness.
Ethics statement
Informed written consent was obtained from all control subjects
and patients prior to inclusion and the study was approved by the
local research ethical committees where patients were recruited
(University of Rome Tor Vergata). Psychiatrists who made the
schizophrenia diagnosis provided advice regarding the patients’
capacity to provide informed consent. The Ethic Committee
discussed this point and approved the methodological procedure
to obtain the informed written consent from all subjects included
in the study.
Genotype analysis
Genomic DNA was isolated from peripheral nuclear blood cells
according to standard procedures. All subjects included in the
present study were genotyped for rs11030100, rs11030099,
rs7124665 and rs6265 BDNF polymorphisms through Sanger
sequencing. Primer oligonucleotides used for amplification
through PCR were respectively: 59-GAGGTGGCTCTGGAAT-
GACATG-39 and 59-CAGCAGATATTCCAAGCATTCC-39;
59-GCAATTGCTGCATCTTAGTAGG-39 and 59-GCCTCC-
CAGGCTTTCAAATAAG-39;5 9–GGTGCAGCTGGAGTT-
TATCAC-39 and 59-GGTCTCGTAGAAGTATTGCTTC-39.
Amplification reaction was performed in a total volume of 25 ml
containing: 200 ng of DNA template, 200 mM of dNTPs (NEB,
Ipswich, MA), 0.3 mM of each primer, 1.5 mM MgCl2, PCR
buffer 16 and 1.5 U of AmpliTaqGold polymerase (Applied
Biosystems, Foster City, CA). An initial denaturation step at 94uC
for 11 min was followed by 30 cycles of amplification at 94uC for
30 sec, 59uC for 30 sec and 72uC for 30 sec. PCR products were
sequenced using Big Dye terminator cycle sequencing kit v3.1
(Applied Biosystems) according to manufacturer’s recommended
protocols. The sequences were analyzed on an automatic
sequencer (3100 Applied Biosystems).
Cell Culture
HeLa cells (ATCC CCL-2) were grown in Dulbecco’s modified
Eagle’s medium (DMEM, Invitrogen), supplemented with 200 U/
ml penicillin, 200 mg/ml streptomycin and 10% heat inactivated
foetal bovine serum (FBS) at 37uC in 95% humidifier air and 5%
CO2.
Luciferase activity assay
39UTR BDNF reference and variant sequences were amplified
from human genomic DNA. The reaction was performed in a total
volume of 25 ml containing: 100 ng of DNA template, 200 mMo f
dNTPs (NEB), 1.2 mM of each primer (59-GTCTAGAGTC-
TTAAAGCAAGGAACACACG;59-GTCTAGACTTCTTGTG-
TATGTACATTGACC), PCR Buffer3 16and 3.75 U of Expand
High Fidelity Enzyme mix (Roche). An initial denaturation step at
94uC for 2 min was followed by 30 cycles (15 sec at 94uC, 30 sec
at 60uC, 1 min at 72uC) and then by a final extension step at 72uC
for 7 min. Fragments were subcloned into the XbaI site in the
39UTR of Renilla luciferase of pRL-TK reporter vector
containing the promoter and the enhancer to express Renilla
luciferase in cotransfected cells. Reporter plasmids (150 ng of
pRL-TK reporter vector, 50 ng of reporter firefly construct -
pGL3 - to standardize for luciferase assay and 100 nM of miRNA
mimics, Dharmacon, Lafayette, CO) were transfected into HeLa
cells (70% confluence) using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. The transfection was
performed in Opti-MEM (Invitrogen), which was removed after
4 h and replaced with Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum. After 24 h cells were lysated
and reporter activity was determined using Dual-luciferase report
assay system (Promega, Madison, WI) according to the manufac-
ture’s protocols. Renilla luciferase activity was normalized to firefly
luciferase activity. Values of luciferase activity were compared
using Student’s t test.
Haplotype analysis
The haplotype structure of subjects heterozygotes for rs6265
and rs11030100/rs11030099 (43 control subjects and 15 patients)
was realized through amplification and cloning of a 3030 bp
fragment containing the three polymorphic sites. PCR was
performed in a total volume of 50 ml containing: 250 ng of
DNA template, 250 mM of dNTPs (NEB), 1 mM of each primer
(59-GGGAAACACTGCATGTCTCTG-39;5 9-ATGCTGGTC-
CAAGTGGTGATC-39), PCR Buffer3 16 and 1,875 U of
Expand Long Template PCR system (Roche, Indianapolis, IN).
An initial denaturation step at 94uC for 3 min was followed by 30
cycles of amplification at 94uC for 30 sec, 65uC for 40 sec and at
68uC for 4 min. The haplotype structure and the LD extent in
both samples were computationally predicted and experimentally
assessed through double restriction enzyme analysis. Fragments
were subcloned in pCR2.1 vector (TA Cloning Kit, Invitrogen,
Carlsbad, CA) according to the manufacturer’s recommended
protocols and subject to enzymatic digestion using PmlI and of
ApoI to detect alleles at rs6265 and rs11030100/rs11030099 sites,
respectively.
Statistical analysis
Hardy-Weinberg equilibrium of the genotypic distributions was
examined using the chi
2 test for goodness of fit. The differences in
genotype and allele frequencies of the observed variants between
cases and controls were evaluated by the chi
2 test. Statistical
significance was defined as p,0.05. Statistical analysis was
conducted using SHEsis software (http://analysis.bio-x.cn [74]).
LD values between alleles of rs6265 and rs11030100/rs11030099
were obtained using the expectation-maximum method (Arlequin
v. 3.11 [73]).
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